UBS AM’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.73M | Sell |
52,192
-1,300
| -2% | -$55K | ﹤0.01% | 2109 |
|
|
2025
Q4 | $2.48M | Sell |
53,492
-3,524
| -6% | -$147K | ﹤0.01% | 1802 |
|
|
2025
Q3 | $1.99M | Sell |
57,016
-37,771
| -40% | -$1.31M | ﹤0.01% | 1749 |
|
|
2025
Q2 | $2.8M | Buy |
94,787
+23,773
| +33% | +$678K | ﹤0.01% | 1991 |
|
|
2025
Q1 | $2.12M | Buy |
71,014
+4,625
| +7% | +$141K | ﹤0.01% | 1967 |
|
|
2024
Q4 | $1.9M | Buy |
66,389
+7,063
| +12% | +$234K | ﹤0.01% | 2071 |
|
|
2024
Q3 | $2.29M | Sell |
59,326
-9,984
| -14% | -$356K | ﹤0.01% | 1970 |
|
|
2024
Q2 | $2.23M | Buy |
69,310
+38,581
| +126% | +$1.34M | ﹤0.01% | 1938 |
|
|
2024
Q1 | $1.19M | Hold |
30,729
| – | – | ﹤0.01% | 1921 |
|
|
2023
Q4 | $946K | Hold |
30,729
| – | – | ﹤0.01% | 2050 |
|
|
2023
Q3 | $687K | Hold |
30,729
| – | – | ﹤0.01% | 2160 |
|
|
2023
Q2 | $737K | Hold |
30,729
| – | – | ﹤0.01% | 2143 |
|
|
2023
Q1 | $737K | Sell |
30,729
-5,927
| -16% | -$157K | ﹤0.01% | 2143 |
|
|
2022
Q4 | $850K | Buy |
36,656
+6,939
| +23% | +$140K | ﹤0.01% | 1926 |
|
|
2022
Q3 | $476K | Buy |
29,717
+1,558
| +6% | +$27.5K | ﹤0.01% | 2363 |
|
|
2022
Q2 | $499K | Sell |
28,159
-556
| -2% | -$9.35K | ﹤0.01% | 2315 |
|
|
2022
Q1 | $585K | Hold |
28,715
| – | – | ﹤0.01% | 2407 |
|
|
2021
Q4 | $536K | Hold |
28,715
| – | – | ﹤0.01% | 2525 |
|
|
2021
Q3 | $567K | Hold |
28,715
| – | – | ﹤0.01% | 2452 |
|
|
2021
Q2 | $679K | Buy |
28,715
+291
| +1% | +$6.72K | ﹤0.01% | 2409 |
|
|
2021
Q1 | $674K | Sell |
28,424
-2,010
| -7% | -$47.7K | ﹤0.01% | 2276 |
|
|
2020
Q4 | $610K | Buy |
30,434
+2,822
| +10% | +$55.1K | ﹤0.01% | 2222 |
|
|
2020
Q3 | $575K | Sell |
27,612
-460
| -2% | -$8.3K | ﹤0.01% | 2080 |
|
|
2020
Q2 | $491K | Sell |
28,072
-224,618
| -89% | -$4.4M | ﹤0.01% | 2135 |
|
|
2020
Q1 | $4.13M | Sell |
252,690
-39,139
| -13% | -$808K | ﹤0.01% | 1112 |
|
|
2019
Q4 | $6.01M | Sell |
291,829
-1,461
| -0.5% | -$24.4K | ﹤0.01% | 1115 |
|
|
2019
Q3 | $3.37M | Sell |
293,290
-4,422
| -1% | -$50.5K | ﹤0.01% | 1373 |
|
|
2019
Q2 | $3.91M | Sell |
297,712
-5,936
| -2% | -$79.4K | ﹤0.01% | 1286 |
|
|
2019
Q1 | $4.6M | Sell |
303,648
-1,633
| -0.5% | -$26.2K | ﹤0.01% | 1182 |
|
|
2018
Q4 | $5.24M | Buy |
305,281
+292,781
| +2,342% | +$5.01M | ﹤0.01% | 1082 |
|
|
2018
Q3 | $184K | Hold |
12,500
| – | – | ﹤0.01% | 2465 |
|
|
2018
Q2 | $298K | Buy |
+12,500
| New | +$307K | ﹤0.01% | 2300 |
|
Other funds holding COLL
EAM
VCM
UBS AM's COLL Position: Q1 2026 in Review
UBS AM reduced its Collegium Pharmaceutical (COLL) stake by 2.4% in Q1 2026, selling an estimated $55K and leaving 52,192 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2109.
UBS AM first reported a position in COLL in Q2 2018 and has held it in 32 quarters since. The position peaked at $6.01M in Q4 2019. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.
- UBS AM held 52,192 shares of Collegium Pharmaceutical worth $1.73M as of Q1 2026.
- UBS AM sold 1,300 Collegium Pharmaceutical shares in Q1 2026, an estimated $55K.
- Collegium Pharmaceutical made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #2109 holding.
- UBS AM first reported a position in Collegium Pharmaceutical in Q2 2018 and has held it in 32 quarters since.
- UBS AM's Collegium Pharmaceutical position peaked at $6.01M in Q4 2019.
- 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.
Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.